| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 4.7% | $2,097,309 | 3,957,186 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 | |||
| Bain Capital Life Sciences Opportunities III, LP | 4.1% | $1,762,227 | 3,538,609 | Bain Capital Life Sciences Opportunities III, LP | 30 Sep 2025 | |||
| Casdin Capital, LLC | 3.7% | $1,702,527 | 3,212,316 | Casdin Capital, LLC | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 20,280,322 | $10,103,490 | -$1,196,912 | $0.498 | 53 |
| 2025 Q2 | 22,628,192 | $12,642,486 | -$3,582,180 | $0.5587 | 64 |
| 2025 Q1 | 29,565,044 | $14,071,235 | -$4,277,613 | $0.476 | 69 |
| 2024 Q4 | 36,396,514 | $36,761,199 | -$7,768,598 | $1.01 | 70 |
| 2024 Q3 | 39,649,193 | $67,797,499 | -$1,211,276 | $1.71 | 66 |
| 2024 Q2 | 40,117,934 | $102,301,880 | +$40,961,743 | $2.55 | 59 |
| 2024 Q1 | 23,113,173 | $96,605,177 | +$22,882,584 | $4.18 | 66 |
| 2023 Q4 | 17,675,436 | $58,683,678 | -$543,594 | $3.32 | 60 |
| 2023 Q3 | 18,060,757 | $36,118,983 | -$2,770,150 | $2 | 53 |
| 2023 Q2 | 19,290,007 | $60,957,915 | -$2,350,461 | $3.16 | 62 |
| 2023 Q1 | 20,016,851 | $69,456,630 | -$4,620,580 | $3.47 | 63 |
| 2022 Q4 | 20,893,156 | $107,178,277 | -$3,631,215 | $5.13 | 65 |
| 2022 Q3 | 21,098,040 | $208,661,435 | -$4,940,964 | $9.89 | 52 |
| 2022 Q2 | 21,756,667 | $182,752,181 | -$3,241,178 | $8.4 | 51 |
| 2022 Q1 | 22,151,698 | $278,859,136 | +$11,504,710 | $12.59 | 51 |
| 2021 Q4 | 21,137,514 | $335,200,000 | +$24,348,825 | $15.86 | 50 |
| 2021 Q3 | 19,798,633 | $496,205,288 | +$62,122,502 | $25.16 | 47 |
| 2021 Q2 | 16,881,896 | $490,834,435 | +$490,834,432 | $29.34 | 35 |